



## Supplementary Figures

Supplementary Figure 1.



**Figure S1.** Nanosight (NTA) Characterization of serum-derived EVs from TBI patients with and without lung injury. NTA analysis showing significant difference in particle concentration (per mL of PBS) between serum-derived EVs from TBI patients with lung injury (n = 13) and TBI patients with no lung injury (n = 8, \*\*  $p < 0.05$ ).

## Supplemental Figure 2.



**Figure S2.** EV depleted isolations do not activate the inflammasome in pulmonary endothelial cells. (A,B) Representative Nanosight analysis shows a 6.9 fold decrease in EVs from  $8.49 \times 10^9$  (EVs) to  $1.25 \times 10^9$  particles/mL (EV depleted) particles/mL from depleted samples. (C,D) Representative Western blots (C) and quantification (D) show that HMVEC-L treated with EV depleted samples have a significantly lower expression of caspase-1, and CD81 after delivery to HMVEC-L ( $n = 3$ , \*  $p < 0.05$ ).